| Date | Title | Description |
| 01.12.2025 | Enlivex: $212 Million Private Placement Announced And Former Italian Prime Minister Matteo Renzi Appointed To Board Of Directors | Enlivex Therapeutics had unveiled significant financing and a prominent board appointment as the company initiates a new digital asset treasury strategy centered on RAIN prediction markets. The clinical-stage immunotherapy company announced... |
| 05.12.2024 | Trump's crypto advocacy steers businesses away from traditional treasury assets | U.S. President-elect Donald Trump's pro-crypto stance is prompting small businesses to allocate portions of their cash to bitcoin, challenging the dominance of traditional assets as companies look for more robust inflation hedges.
Over the ... |
| 29.05.2024 | Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering | - |
| 28.05.2024 | Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering | Single healthcare-focused institutional investor
$5 million upfront with up to an additional $10 million of gross proceeds upon the exercise in full of clinical milestone-linked warrants
Nes-Ziona, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- E... |
| 13.12.2021 | Enlivex Therapeutics : Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece - Form 6-K | Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece
Nes-Ziona, Israel, December 13, 2021 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENL... |
| 13.12.2021 | Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece | Nes-Ziona, Israel, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that, following a review of the Company’s preclin... |
| 07.12.2021 | Enlivex Therapeutics : Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece - Form 6-K | Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece
Nes-Ziona, Israel, December 7, 2021 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage ... |
| 07.12.2021 | Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece | Nes-Ziona, Israel, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that, following a review of the Company’s preclin... |
| 06.12.2021 | Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Treatment of Sepsis Patients with Allocetra | Nes-Ziona, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Patent and Trademark Office issued ... |
| 06.12.2021 | Enlivex Therapeutics : Receives Notice of Allowance for U.S. Patent Application Covering the Treatment of Sepsis Patients with Allocetra - Form 6-K | Enlivex Receives Notice of Allowance for U.S. Patent Application
Covering the Treatment of Sepsis Patients with Allocetra
Nes-Ziona, Israel, December 6, 2021 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"... |
| 22.11.2021 | Enlivex Therapeutics : Initiated dosing in placebo-controlled Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with ARDS - Form 6-K | Initiated dosing in placebo-controlled Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with ARDS
Received authorization to expand ongoing sepsis and COVID-19 trials into Spain
Initiated design and co... |
| 22.11.2021 | Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update | Initiated dosing in placebo-controlled Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with ARDS
Received authorization to expand ongoing sepsis and COVID-19 trials into Spain
Initiated design and co... |
| 04.11.2021 | Spanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Phase II into Spain | Nes Ziona, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Spanish Agency of Medicines and Medical ... |
| 04.11.2021 | Spanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Phase II into Spain - Form 6-K | Spanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Phase II into Spain
Nes Ziona, Israel, November 4, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage r... |
| 12.10.2021 | Enlivex Therapeutics : CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine | Publication follows the Israeli Ministry of Health’s appointment of
Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines
Nes-Ziona, Israel, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd... |
| 05.10.2021 | Enlivex Therapeutics : Receives Notice of Allowance for Israeli Patent Application Covering Allocetra Derived from Pooled Donor Cells | Nes-Ziona, Israel, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 a... |
| 05.10.2021 | Enlivex Therapeutics : Receives Notice of Allowance for Israeli Patent Application Covering Allocetra Derived from Pooled Donor Cells (Form 6-K) | Enlivex Receives Notice of Allowance for Israeli Patent Application
Covering Allocetra Derived from Pooled Donor Cells
Nes-Ziona, Israel, October 5, 2021 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), ... |
| 04.10.2021 | Enlivex Therapeutics : Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data from Phase Ib Trial Evaluating Allocetra in Patients with Sepsis | Nes-Ziona, Israel, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the peer-reviewed publication of clinical data fr... |
| 04.10.2021 | Enlivex Therapeutics : Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data from Phase Ib Trial Evaluating Allocetra in Patients with Sepsis (Form 6-K) | Enlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data from Phase Ib Trial Evaluating Allocetra in Patients with Sepsis
Data published in Frontiers in Immunology show a robust safety profile and substant... |
| 09.08.2021 | Enlivex Therapeutics : Announces Second Quarter 2021 Financial Results and Provides a Business Update | Top-line results from Phase IIb sepsis trial expected in Q2 2022Phase IIb trial in severe and critical COVID-19 patients planned for initiation in Q3 2021Initiation of a Phase Ib trial evaluating AllocetraTM in combination with chemotherapy... |
| 12.07.2021 | Enlivex Therapeutics : Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant | Nes Ziona, Israel, July 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it has initiated the design and construction... |
| 15.06.2021 | ENLIVEX THERAPEUTICS LTD.
Enlivex Therapeutics : Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cyto... | Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer
Nes-Ziona, Israel, June 15,... |
| 15.06.2021 | ENLIVEX THERAPEUTICS LTD.
Enlivex Therapeutics : Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cyto... | Nes-Ziona, Israel, June 15, 2021 (GLOBE NEWSWIRE) -- – Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-1... |
| 01.06.2021 | ENLIVEX THERAPEUTICS LTD.
Enlivex Therapeutics : Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy | Nes-Ziona, Israel, June 01, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 ... |
| 01.06.2021 | ENLIVEX THERAPEUTICS LTD.
Enlivex Therapeutics : Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy (Form 6-K) | Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions,
Manufacturing Methods and Uses of Allocetra Immunotherapy
Nes-Ziona, Israel, June 1, 2021 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd., (Nasdaq: ENLV, t... |
| 12.02.2021 | Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares | Nes Ziona, Israel, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors... |
| 25.09.2017 | Korea Investment Partners backs $8m investment in Enlivex Therapeutics | Premium
Korea Investment Partners (KIP) and Tel Aviv-listed biotechnology enterprise Hadasit Bio Holdings Ltd. have backed an $8 million equity investment in Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, at a valuation ... |
| 20.09.2017 | Term Sheet — Wednesday, September 20 | THE ROBOTS ARE COMING
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
It is so massive—its investors range from a Saudi sovereign wealth fund to Apple—that small stakes are impossible ... |
